| HYOGO COLLEGE OF MEDICINE Patent applications |
| Patent application number | Title | Published |
|---|
| 20110281284 | NOVEL LIVER CANCER MARKER - According to the present invention, HDGF in the blood of patients with chronic liver disease is measured to diagnose whether the patients have liver cancer. A measurement kit for the diagnosis is also provided. | 11-17-2011 |
| 20110252487 | COMPOSITION FOR INDUCING TH2 CELL, THERAPEUTIC COMPOSITION FOR TH2-TYPE DISEASE, AND USE OF SAME - The present invention provides a complex of an antigen and IgE binding to the antigen, a composition including an antigen and IgE binding to the antigen, and a method of using the complex or the composition. With the present invention, it is possible to induce naive T cells to develop into Th2 cells. Moreover, the present invention clarified a working mechanism of a Th2-type immune response, particularly a production mechanism of early IL-4. With use of the present invention, it is possible to provide a technique of treating and preventing Th2-type diseases. | 10-13-2011 |
| 20100035853 | METHOD FOR PREVENTING OR TREATING CISPLATIN-INDUCED NEPHROTOXICITY - Provided is a method for preventing or treating cisplatin induced nephrotoxicity, which comprises administering a patient who is receiving cisplatin a therapeutically effective amount of an aldosterone blocker such as eplerenone or spironolactone. | 02-11-2010 |
| 20100009447 | Vgamma9Vdelta2 T cell proliferation agent, method for producing activated Vgamma9Vdelta2 T cells, and uses thereof - A Vγ9Vδ2 T cell proliferation agent includes at least a bisphosphonate, interleukin 2, and interleukin 18. Since has properties that improve cell viability by inhibiting cell death, IL-18 is presumably capable of acting as a cofactor for the bisphosphonate so as to significantly increase the effect of Vγ9Vδ2 T cell proliferation by the bisphosphonate and the IL-2. This allows providing a Vγ9Vδ2 T cell proliferation agent capable of growing Vγ9Vδ2 T cells with a proliferated efficiency significantly high compared to conventional methods so that the proliferated Vγ9Vδ2 T cells have a high antitumor activity and high cytokine productivity. | 01-14-2010 |
